The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Response of patients with refractory myasthenia gravis to rituximab: a retrospective study
Open accessAbstract
Introduction: Myasthenia gravis, an autoimmune disorder of neuromuscular transmission, is treated by an array of immunomodulating therapies. A variable response is observed with certain patients being medically refractory. Methods: We report the results of 14 refractory generalized myasthenia gravis patients (6 AChR+; 8 MuSK+) treated with rituximab. Results: Sustained clinical improvement was observed in all patients as well as a reduction of conventional immunotherapies. Prednisone dose decreased a mean of 65.1%, 85.7%, and 93.8% after cycle 1, 2, and 3 of rituximab therapy, respectively. A statistically significant reduction in plasma exchange sessions was seen after cycle 1 with all patients being off of plasma exchange after cycle 3. Acetylcholine receptor antibody titers decreased a mean of 52.1% ( p = 0.0046) post-cycle 2. Conclusion: Our results support the hypothesis that rituximab is beneficial and well tolerated in managing refractory myasthenia gravis and nearly doubles published cases. We propose that B-cell-directed therapies may become an attractive option and suggest pursuit of a prospective trial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Cited by
Rituximab treatment of myasthenia gravis: A systematic review: Rituximab in Myasthenia Gravis
Tandan, R., Hehir, M. K., Waheed, W., & Howard, D. B. (2017) · Muscle & Nerve · doi:10.1002/mus.25597 · Cited by 275
Mensah, F., Bansal, A., Berkovitz, S., Sharma, A., Reddy, V, Leandro, M. J., & Cambridge, G. (2016) · Clinical and Experimental Immunology · doi:10.1111/cei.12749 · Cited by 34
Song, J., Lei, X., Jiao, W., Song, Y., Chen, W., Li, J., & Chen, Z. (2018) · Scientific Reports · doi:10.1038/s41598-018-26918-z · Cited by 28
Metadata
- Authors
- Nowak, R. J., DiCapua, D. B., Zebardast, N., & Goldstein, J. M.
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2011-07-04
- Volume
- 4
- Issue
- 5
- Pages
- 259-266
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- OpenAlex
- W2021398160
- Cited by
- 158
- References
- 1
- FWCI
- 4.76
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. https://app.cochat.ai/papers/10.1177/1756285611411503
- The paper
- Nowak, R. J., DiCapua, D. B., Zebardast, N., & Goldstein, J. M. (2011). Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Therapeutic Advances in Neurological Disorders. https://doi.org/10.1177/1756285611411503
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.